EFSA IPE Fiber Ruling: Safe in Food, Not a Diet Fix

Inulin-propionate ester is now safe to add to food in the EU — a safety ruling, not a weight-loss result; the trial found no difference in weight gain vs a plain-fiber control, so the ‘food Ozempic’ framing exceeds the evidence.

Europe’s food-safety body ruled inulin-propionate ester safe to add to food — a safety judgment that measured no appetite or weight outcome. The “food Ozempic” framing rests on separate, smaller trials; the largest and longest found no difference in weight gain from a plain inulin control.

What this means

The European Food Safety Authority judged inulin-propionate ester (IPE) safe to add to cereal bars, fruit-smoothie-type drinks and bread and rolls, at doses up to 20 g/day for up to 12 months. That is a safety ruling, not a weight-loss result: the opinion reports no appetite or weight outcome, so it cannot support a claim that the fiber makes people eat less. The “eat less” idea comes from separate, smaller trials, and the largest and longest — 12 months in 270 adults — found no difference in weight gain from an inulin control (adjusted difference 1.02 kg, about 2.2 lb; 95% CI -0.37 to 2.41; p=0.15).

A safety ruling, not a weight-loss result

The European Food Safety Authority (EFSA) assessed inulin-propionate ester (IPE) as a novel food — an ingredient not widely eaten in the EU before — and concluded it is safe for the general population in the products proposed: bread and rolls, cereal bars and fruit-smoothie-type drinks. Doses up to 20 g/day for up to 12 months were considered. It is a safety opinion: it reports no appetite, energy-intake, weight or GLP-1 outcome of its own, and says nothing about whether the fiber reduces how much anyone eats. Estimated high-end daily intake from those foods is about 8.5 g/day for vegetarians.

Where the “eat less” claim comes from

The appetite claim rests on separate IPE trials, not on the EFSA opinion. In a 24-week randomized trial in 60 overweight adults (Chambers et al., Gut 2015), 10 g/day of IPE against inulin lowered acute ad-libitum energy intake by 13.8% (1,175 to 1,013 kcal). The between-group 24-week weight change was -1.40 kg (about -3.1 lb), with a confidence interval spanning no effect (p=0.099). A seven-day crossover study of 21 completers (Byrne et al., Nutrients 2019) found only a trend toward lower energy intake versus control, and no difference in the satiety hormones GLP-1 or PYY.

The largest, longest trial was null

The largest and longest test is iPREVENT (Pugh et al., eClinicalMedicine 2024): 10 g/day of IPE against inulin for 12 months in 270 adults aged 20-40. It found no significant difference in baseline-adjusted weight gain — an adjusted difference of 1.02 kg (about 2.2 lb; 95% CI -0.37 to 2.41; p=0.15). Whether IPE durably reduces how much people eat is therefore unresolved, and the positive findings come from small, short studies.

Funding, interests and access

EFSA is an EU public agency; panel members’ interests are handled under its independence policy, and there was no industry funding of the assessment. IPE is a commercially held ingredient, and parts of the applicant’s dossier — batch analyses and in-house analytical methods — were claimed as proprietary, so the underlying data are not fully public. The drugs the “food Ozempic” label borrows from are covered separately on this site (what-happens-when-people-stop-weight-loss-medications).

Terms explained

Inulin-propionate ester (IPE): a manufactured fiber that bonds propionate, a short-chain fatty acid, to inulin so the acid is released in the colon rather than earlier in the gut.
Novel food opinion: a safety assessment, under EU rules, of a food ingredient not significantly eaten in Europe before; it judges whether the ingredient is safe at the proposed uses, not whether it delivers a benefit.
Propionate: a short-chain fatty acid produced when gut bacteria ferment fiber; it is one of the signals involved in appetite and metabolism.
GLP-1 and PYY: gut hormones released after eating that contribute to a sense of fullness. Weight-loss drugs mimic GLP-1, which is why a fiber that raises it draws the “food Ozempic” comparison.

Sources

Primary source: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA); Turck D, Bohn T, et al. “Safety of inulin-propionate ester as a novel food pursuant to Regulation (EU) 2015/2283.” EFSA Journal 2025;23(7):e9534, published 2025-07-24. DOI: 10.2903/j.efsa.2025.9534 · PMID: 40708711 · PMCID: PMC12287749. Peer-reviewed regulatory safety opinion, not an efficacy trial; full text read (open access, CC BY-ND). It reports no appetite, energy-intake or weight endpoint.
Efficacy — 24-week randomized trial: Chambers et al. “Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.” Gut 2015. DOI: 10.1136/gutjnl-2014-307913 · PMID: 25500202 · PMCID: PMC4680171. Full text read (open access).
Efficacy — crossover study: Byrne et al. “Effects of Inulin Propionate Ester Incorporated into Palatable Food Products on Appetite and Resting Energy Expenditure: A Randomised Crossover Study.” Nutrients 2019. DOI: 10.3390/nu11040861 · PMID: 30995824 · PMCID: PMC6520886. Full text read (open access).
Efficacy — the null trial: Pugh et al. “Increase in colonic PRopionate as a method of prEVENTing weight gain over 12 months in adults aged 20-40 years (iPREVENT): a multi-centre, double-blind, randomised, parallel-group trial.” eClinicalMedicine 2024. DOI: 10.1016/j.eclinm.2024.102844 · PMID: 39391015 · PMCID: PMC11466568. Full text read (open access).
Press signal (discovery and framing only, not evidence): “Why a type of GLP-1 weight loss fibre could soon be added to food to make you eat less.” The Independent, 2026-07-08. https://www.independent.co.uk/life-style/food-and-drink/weight-loss-diet-glp1-ozempic-mounjaro-fibre-appetite-suppression-b3009603.html